

Clinical Trial Protocol

Iranian Registry of Clinical Trials

23 Feb 2026

Investigating effect of Spirulina (*Arthrospira platensis*) dietary supplementation on COVID-19 disease outcomes in patients admitted to Intensive Care Units of hospitals: phase 2 clinical trial

Protocol summary

Study aim

Main objective: to determine and comparison effect of Spirulina (*Arthrospira Platensis*) supplement on COVID-19 disease's outcomes (consisted of laboratory measures ; ventilator free days;) LOS ICU (length of stay in ICU); LOS Hospital (length of hospital stay) and mortality rate; clinical manifestations; severity and nutritional status) in patients admitted to intensive care units of hospitals during 4 weeks between intervention and control groups.

Design

Randomized control trial, with control group, randomization using Random Number Table, phase 2 on patients with COVID-19

Settings and conduct

The study will be carried out among COVID-19 patients admitted in ICU hospitals. Spirulina supplement will be taken to patients during 28 days and the outcomes will be followed.

Participants/Inclusion and exclusion criteria

Patients with positive PCR admitted in ICU will be included. Patients under 18 years of age; pregnant and lactating women and consumers of vitamins C and E, omega-3 and antioxidant supplements in the last 3 months; patients with severe renal failure; liver failure of the last stage (cirrhosis); uncontrolled hypertension; patients who do not have a functioning gastrointestinal tract and have not been prescribed oral or intravenous nutrition and also with drug / food allergies will be excluded in this study.

Intervention groups

Intervention group are COVID-19 patients with routine drugs and 5gr/day Spirulina powder. Control group without placebo and take normal therapeutic drugs.

Main outcome variables

IL6; ESR; CRP; O2SAT

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20200720048139N1**

Registration date: **2020-11-09, 1399/08/19**

Registration timing: **prospective**

Last update: **2020-11-09, 1399/08/19**

Update count: **0**

Registration date

2020-11-09, 1399/08/19

Registrant information

Name

Monireh Hatami

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 21 2200 2040

Email address

hatami@iaups.ac.ir

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2020-11-21, 1399/09/01

Expected recruitment end date

2021-03-20, 1399/12/30

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Investigating effect of Spirulina (Arthrospira platensis) dietary supplementation on COVID-19 disease outcomes in patients admitted to Intensive Care Units of hospitals: phase 2 clinical trial

Public title

Investigating effect of Spirulina dietary supplementation on COVID-19 disease outcomes in patients admitted to Intensive Care Units

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria:

All covid-19 patients confirmed with PCR test admitted to the ICU are entered the trial

Exclusion criteria:

Age less than 18 Women during pregnancy and lactation Consumers of supplements C, E, Omega 3, Antioxidants in the last 3 months Patients with severe renal failure Patients with liver failure last stage (cirrhosis) Patients with uncontrolled hypertension Patients who do not have a functioning gastrointestinal tract and have not been prescribed oral or intravenous nutrition Patients with drug / food allergies

Age

From **18 years** old

Gender

Both

Phase

2

Groups that have been masked

No information

Sample size

Target sample size: **138**

Randomization (investigator's opinion)

Randomized

Randomization description

Simple randomization is used to identify samples in the control or intervention group. We will put 138 small envelopes containing random numbers obtained from the table of random numbers (69 evens and 69 odds) and the consent form inside a large envelope. The even numbers belong to the intervention group and odd numbers belong to the control group. The patient (if the patient is not conscious the person in private care of the patient) is asked to take one of the envelopes and will be placed in one of the control or intervention groups based on the number taken.

Blinding (investigator's opinion)

Not blinded

Blinding description

Placebo

Not used

Assignment

Parallel

Other design features

In this study, we have an intervention group and a control group. Intervention group will receive 5 grams of spirulina supplement in addition to routine medications and control group will not receive anything other than routine medications.

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Ethics Committee of Islamic Azad Tehran Medical Sciences University-Pharmacy and Pharmaceutical Bran

Street address

Faculty of Pharmacy and Pharmaceutical Branches, Yakhchal Street, Shariati Street, Tehran, Iran

City

Tehran

Province

Tehran

Postal code

1941933111

Approval date

2020-06-07, 1399/03/18

Ethics committee reference number

IR.IAU.PS.REC.1399.063

Health conditions studied

1

Description of health condition studied

COVID-19

ICD-10 code

U07.1

ICD-10 code description

بیماری کووید-19 تایید شده با تستهای آزمایشگاهی

Primary outcomes

1

Description

IL6

Timepoint

The first and 28th of the study

Method of measurement

Blood Sample method: ELISA ; sensitivity 0.06 pg/ml

2

Description

ESR (Erythrocyte sedimentation rate)

Timepoint

The first and 28th of the study

Method of measurement

Automated Modified Westergren

3

Description

CRP

Timepoint

The first and 28th of the study

Method of measurement

Blood sampling- ELISA

4

Description

Nutrition Status

Timepoint

the first and 28th of the study

Method of measurement

Nutric-score Questionnaire

5

Description

Fever

Timepoint

Daily

Method of measurement

Digital Thermometer

6

Description

O2 SATURATION

Timepoint

Duration the stay in ICU

Method of measurement

Pulse Oxymeter

Secondary outcomes

1

Description

Duration of Stay in ICU

Timepoint

Since the first day till end of stay in ICU

Method of measurement

OBSERVATION

2

Description

Ventilator Free days

Timepoint

During the stay in ICU

Method of measurement

Observation

3

Description

Mortality Rate

Timepoint

During the stay in ICU

Method of measurement

Observation

Intervention groups

1

Description

Intervention group: COVID-19 patients hospitalized in ICU

Category

Treatment - Other

Recruitment centers

1

Recruitment center

Name of recruitment center

Farhikhtegan Hospital

Full name of responsible person

Mahdi Shadnoush

Street address

Hesarak, Shohadaye Hesarak Blvd

City

Tehran

Province

Tehran

Postal code

1477899679

Phone

+98 21 4486 7262

Fax

+98 21 4484 5171

Email

farhikhteganhospital@gmail.com

Web page address

<http://farhikhtegan.iautmu.ac.ir>

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Islamic Azad University

Full name of responsible person

Farshad Hashemian

Street address

Islamic Azad University, Tehran Medical Sciences,
Shariati Street

City

Tehran

Province

Tehran

Postal code

1916893813

Phone

+98 21 2200 6660

Email

hashemian.f@iaups.ac.ir

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Islamic Azad University

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding*empty***Country of origin****Type of organization providing the funding**

Academic

Person responsible for general inquiries**Contact****Name of organization / entity**

Islamic Azad University

Full name of responsible person

Monireh Hatami

Position

Assistant Proffessor

Latest degree

Ph.D.

Other areas of specialty/work

Nutrition

Street address

Faculty of Farmacy, Yakhchal Street, Shariati Street,

City

Tehran

Province

Tehran

Postal code

1941933111

Phone

+98 21 2200 2040

Email

mhnutr@gmail.com

Person responsible for scientific inquiries**Contact****Name of organization / entity**

Shahid Beheshti University of Medical Sciences

Full name of responsible person

Mahdi Shadnoush

Position

Associte Professor

Latest degree

Specialist

Other areas of specialty/work

Nutrition

Street address

Shahid Beheshti University of Medical Sciences, 7th

Floo, Arabi Ave, Daneshjoo Blvd, Velenjak

City

Teran

Province

Tehran

Postal code

19839-63113

Phone

+98 21 2243 9798

Fax

+98 21 2243 9798

Email

mshadnoush@gmail.com

Person responsible for updating data**Contact****Name of organization / entity**

Islamic Azad University

Full name of responsible person

Monireh Hatami

Position

Assistant Professor

Latest degree

Ph.D.

Other areas of specialty/work

Nutrition

Street address

Faculty of Pharmacy, Yakhchal St., Shariati St.

City

Tehran

Province

Tehran

Postal code

1941933111

Phone

+98 21 2200 2040

Email

mhnutr@gmail.com

Sharing plan**Deidentified Individual Participant Data Set (IPD)**

Undecided - It is not yet known if there will be a plan to make this available

Study Protocol

Undecided - It is not yet known if there will be a plan to make this available

Statistical Analysis Plan

Undecided - It is not yet known if there will be a plan to make this available

Informed Consent Form

Undecided - It is not yet known if there will be a plan to make this available

Clinical Study Report

Undecided - It is not yet known if there will be a plan to make this available

Analytic Code

Undecided - It is not yet known if there will be a plan to make this available

Data Dictionary

Undecided - It is not yet known if there will be a plan to make this available